Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Michael Heinrich
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Physiology
Disorders
Anatomy
Procedures
Living Beings
Sign-in to see full Profile
Network (preview)
53
Corless, Christopher
29
Druker, Brian
21
Demetri, George
20
Fletcher, Jonathan
20
Deininger, Michael
15
McGreevey, Laura
13
Blanke, Charles
12
Bagby, Grover
12
Fletcher, Christopher
12
Town, Ajia
8
von Mehren, Margaret
8
Stoffregen, Eric
8
Griffith, Diana
8
Keeble, Winifred
7
Joensuu, Heikki
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Michael Heinrich (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Demetri George D; Heinrich Michael C; Fletcher Jonathan A; Fletcher Christopher D M; Van den Abbeele Annick D; Corless Christopher L; Antonescu Cristina R; George Suzanne; Morgan Jeffrey A; Chen Ming Hui; Bello Carlo L; Huang Xin; Cohen Darrel P; Baum Charles M; Maki Robert G
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(18):5902-9.
-
2009: Rink Lori; Skorobogatko Yuliya; Kossenkov Andrew V; Belinsky Martin G; Pajak Thomas; Heinrich Michael C; Blanke Charles D; von Mehren Margaret; Ochs Michael F; Eisenberg Burton; Godwin Andrew K
Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor.
Molecular cancer therapeutics 2009;8(8):2172-82.
-
2009: Schittenhelm Marcus M; Kampa Kerstin M; Yee Kevin W H; Heinrich Michael C
The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin.
Cell cycle (Georgetown, Tex.) 2009;8(16):2621-30.
-
2009: Janeway Katherine A; Albritton Karen H; Van Den Abbeele Annick D; D'Amato Gina Z; Pedrazzoli Paolo; Siena Salvatore; Picus Joel; Butrynski James E; Schlemmer Marcus; Heinrich Michael C; Demetri George D
Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Pediatric blood & cancer 2009;52(7):767-71.
-
2009: Tyner Jeffrey W; Deininger Michael W; Loriaux Marc M; Chang Bill H; Gotlib Jason R; Willis Stephanie G; Erickson Heidi; Kovacsovics Tibor; O'Hare Thomas; Heinrich Michael C; Druker Brian J
RNAi screen for rapid therapeutic target identification in leukemia patients.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(21):8695-700.
-
2009: Ustun Celalettin; Corless Christopher L; Savage Natasha; Fiskus Warren; Manaloor Elizabeth; Heinrich Michael C; Lewis Grant; Ramalingam Preetha; Kepten Ilana; Jillella Anand; Bhalla Kapil
Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.
Leukemia research 2009;33(5):735-41.
-
2009: Schittenhelm Marcus M; Kollmannsberger Christian; Oechsle Karin; Harlow Amy; Morich Jason; Honecker Friedemann; Kurek Raffael; Störkel Stephan; Kanz Lothar; Corless Christopher L; Wong Kwok-Kin; Bokemeyer Carsten; Heinrich Michael C
Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer.
Molecular cancer therapeutics 2009;8(3):481-9.
-
2009: Tyner Jeffrey W; Erickson Heidi; Deininger Michael W N; Willis Stephanie G; Eide Christopher A; Levine Ross L; Heinrich Michael C; Gattermann Norbert; Gilliland D Gary; Druker Brian J; Loriaux Marc M
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.
Blood 2009;113(8):1749-55.
-
2009: Hess Corine J; Feller Nicole; Denkers Fedor; Kelder Angèle; Merle Pauline A; Heinrich Michael C; Harlow Amy; Berkhof Johannes; Ossenkoppele Gert J; Waisfisz Quinten; Schuurhuis Gerrit J
Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia.
Haematologica 2009;94(1):46-53.
-
2009: Eisenberg Burton L; Harris Jonathan; Blanke Charles D; Demetri George D; Heinrich Michael C; Watson James C; Hoffman John P; Okuno Scott; Kane John M; von Mehren Margaret
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.
Journal of surgical oncology 2009;99(1):42-7.
-
2008: Jiang Xiaofeng; Zhou Jun; Yuen Noah K; Corless Christopher L; Heinrich Michael C; Fletcher Jonathan A; Demetri George D; Widlund Hans R; Fisher David E; Hodi F Stephen
Imatinib targeting of KIT-mutant oncoprotein in melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7726-32.
-
2008: Agarwal A; Eide C A; Harlow A; Corbin A S; Mauro M J; Druker B J; Corless C L; Heinrich M C; Deininger M W
An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(12):2269-72.
-
2008: Beadling Carol; Jacobson-Dunlop Erick; Hodi F Stephen; Le Claudia; Warrick Andrea; Patterson Janice; Town Ajia; Harlow Amy; Cruz Frank; Azar Sharl; Rubin Brian P; Muller Susan; West Rob; Heinrich Michael C; Corless Christopher L
KIT gene mutations and copy number in melanoma subtypes.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(21):6821-8.
-
2008: Heinrich Michael C; Maki Robert G; Corless Christopher L; Antonescu Cristina R; Harlow Amy; Griffith Diana; Town Ajia; McKinley Arin; Ou Wen-Bin; Fletcher Jonathan A; Fletcher Christopher D M; Huang Xin; Cohen Darrel P; Baum Charles M; Demetri George D
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(33):5352-9.
-
2008: Heinrich Michael C; Owzar Kouros; Corless Christopher L; Hollis Donna; Borden Ernest C; Fletcher Christopher D M; Ryan Christopher W; von Mehren Margaret; Blanke Charles D; Rankin Cathryn; Benjamin Robert S; Bramwell Vivien H; Demetri George D; Bertagnolli Monica M; Fletcher Jonathan A
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(33):5360-7.
-
2008: Raymond Eric; Brandes Alba A; Dittrich Christian; Fumoleau Pierre; Coudert Bruno; Clement Paul M J; Frenay Marc; Rampling Roy; Stupp Roger; Kros Johan M; Heinrich Michael C; Gorlia Thierry; Lacombe Denis; van den Bent Martin J;
Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(28):4659-65.
-
2008: Liegl B; Kepten I; Le C; Zhu M; Demetri G D; Heinrich M C; Fletcher C D M; Corless C L; Fletcher J A
Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
The Journal of pathology 2008;216(1):64-74.
-
2008: Heinrich Michael C; Joensuu Heikki; Demetri George D; Corless Christopher L; Apperley Jane; Fletcher Jonathan A; Soulieres Denis; Dirnhofer Stephan; Harlow Amy; Town Ajia; McKinley Arin; Supple Shane G; Seymour John; Di Scala Lilla; van Oosterom Allan; Herrmann Richard; Nikolova Zariana; McArthur And Grant;
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(9):2717-25.
-
2008: Loriaux Marc M; Levine Ross L; Tyner Jeffrey W; Fröhling Stefan; Scholl Claudia; Stoffregen Eric P; Wernig Gerlinde; Erickson Heidi; Eide Christopher A; Berger Roland; Bernard Olivier A; Griffin James D; Stone Richard M; Lee Benjamin; Meyerson Matthew; Heinrich Michael C; Deininger Michael W; Gilliland D Gary; Druker Brian J
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.
Blood 2008;111(9):4788-96.
-
2008: Hodi F Stephen; Friedlander Philip; Corless Christopher L; Heinrich Michael C; Mac Rae Suzanne; Kruse Andrea; Jagannathan Jyothi; Van den Abbeele Annick D; Velazquez Elsa F; Demetri George D; Fisher David E
Major response to imatinib mesylate in KIT-mutated melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(12):2046-51.
-
2008: Lasota Jerzy; Corless Christopher L; Heinrich Michael C; Debiec-Rychter Maria; Sciot Raf; Wardelmann Eva; Merkelbach-Bruse Sabine; Schildhaus Hans-Ulrich; Steigen Sonja E; Stachura Jerzy; Wozniak Agnieszka; Antonescu Cristina; Daum Ondrej; Martin Javier; Del Muro Javier Garcia; Miettinen Markku
Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2008;21(4):476-84.
-
2008: Subramanian S; Lui W O; Lee C H; Espinosa I; Nielsen T O; Heinrich M C; Corless C L; Fire A Z; van de Rijn M
MicroRNA expression signature of human sarcomas.
Oncogene 2008;27(14):2015-26.
-
2008: Blanke Charles D; Rankin Cathryn; Demetri George D; Ryan Christopher W; von Mehren Margaret; Benjamin Robert S; Raymond A Kevin; Bramwell Vivien H C; Baker Laurence H; Maki Robert G; Tanaka Michael; Hecht J Randolph; Heinrich Michael C; Fletcher Christopher D M; Crowley John J; Borden Ernest C
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):626-32.
-
2008: Blanke Charles D; Demetri George D; von Mehren Margaret; Heinrich Michael C; Eisenberg Burton; Fletcher Jonathan A; Corless Christopher L; Fletcher Christopher D M; Roberts Peter J; Heinz Daniela; Wehre Elisabeth; Nikolova Zariana; Joensuu Heikki
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):620-5.
-
2008: Espinosa Inigo; Lee Cheng-Han; Kim Mi Kyung; Rouse Bich-Tien; Subramanian Subbaya; Montgomery Kelli; Varma Sushama; Corless Christopher L; Heinrich Michael C; Smith Kevin S; Wang Zhong; Rubin Brian; Nielsen Torsten O; Seitz Robert S; Ross Douglas T; West Robert B; Cleary Michael L; van de Rijn Matt
A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors.
The American journal of surgical pathology 2008;32(2):210-8.
-
2008: Tyner Jeffrey W; Walters Denise K; Willis Stephanie G; Luttropp Mary; Oost Jason; Loriaux Marc; Erickson Heidi; Corbin Amie S; O'Hare Thomas; Heinrich Michael C; Deininger Michael W; Druker Brian J
RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia.
Blood 2008;111(4):2238-45.
-
2008: Corless Christopher L; Heinrich Michael C
Molecular pathobiology of gastrointestinal stromal sarcomas.
Annual review of pathology 2008;3():557-86.
-
2007: Fröhling Stefan; Scholl Claudia; Levine Ross L; Loriaux Marc; Boggon Titus J; Bernard Olivier A; Berger Roland; Döhner Hartmut; Döhner Konstanze; Ebert Benjamin L; Teckie Sewit; Golub Todd R; Jiang Jingrui; Schittenhelm Marcus M; Lee Benjamin H; Griffin James D; Stone Richard M; Heinrich Michael C; Deininger Michael W; Druker Brian J; Gilliland D Gary
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.
Cancer cell 2007;12(6):501-13.
-
2007: Aubry Marie-Christine; Heinrich Michael C; Molina Julian; Lewis Jean E; Yang Ping; Cassivi Stephen D; Corless Christopher L
Primary adenoid cystic carcinoma of the lung: absence of KIT mutations.
Cancer 2007;110(11):2507-10.
-
2007: Janeway Katherine A; Liegl Bernadette; Harlow Amy; Le Claudia; Perez-Atayde Antonio; Kozakewich Harry; Corless Christopher L; Heinrich Michael C; Fletcher Jonathan A
Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.
Cancer research 2007;67(19):9084-8.
-
2007: Desai Jayesh; Shankar Sridhar; Heinrich Michael C; Fletcher Jonathan A; Fletcher Christopher D; Manola Judi; Morgan Jeffrey A; Corless Christopher L; George Suzanne; Tuncali Kemal; Silverman Stuart G; Van den Abbeele Annick D; van Sonnenberg Eric; Demetri George D
Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 1):5398-405.
-
2007: Schmidt Jason; Derr Victoria; Heinrich Michael C; Crum Christopher P; Fletcher Jonathan A; Corless Christopher L; Nosé Vânia
BRAF in papillary thyroid carcinoma of ovary (struma ovarii).
The American journal of surgical pathology 2007;31(9):1337-43.
-
2007: Agaimy Abbas; Pelz Antje-Friederike; Corless Christopher L; Wünsch Peter H; Heinrich Michael C; Hofstaedter Ferdinand; Dietmaier Wolfgang; Blanke Charles D; Wieacker Peter; Roessner Albert; Hartmann Arndt; Schneider-Stock Regine
Epithelioid gastric stromal tumours of the antrum in young females with the Carney triad: a report of three new cases with mutational analysis and comparative genomic hybridization.
Oncology reports 2007;18(1):9-15.
-
2007: Gu Ting-lei; Mercher Thomas; Tyner Jeffrey W; Goss Valerie L; Walters Denise K; Cornejo Melanie G; Reeves Cynthia; Popova Lana; Lee Kimberly; Heinrich Michael C; Rush John; Daibata Masanori; Miyoshi Isao; Gilliland D Gary; Druker Brian J; Polakiewicz Roberto D
A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia.
Blood 2007;110(1):323-33.
-
2007: Rubin Brian P; Heinrich Michael C; Corless Christopher L
Gastrointestinal stromal tumour.
Lancet 2007;369(9574):1731-41.
-
2007: Sherbenou D W; Wong M J; Humayun A; McGreevey L S; Harrell P; Yang R; Mauro M; Heinrich M C; Press R D; Druker B J; Deininger M W
Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(3):489-93.
-
2007: Stewart Douglas R; Corless Christopher L; Rubin Brian P; Heinrich Michael C; Messiaen Ludwine M; Kessler Lisa J; Zhang Paul J; Brooks David G
Mitotic recombination as evidence of alternative pathogenesis of gastrointestinal stromal tumours in neurofibromatosis type 1.
Journal of medical genetics 2007;44(1):e61.
-
2007: Coffey Robert J; Washington Mary Kay; Corless Christopher L; Heinrich Michael C
Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach.
The Journal of clinical investigation 2007;117(1):70-80.
-
2006: DeAngelo Daniel J; Stone Richard M; Heaney Mark L; Nimer Stephen D; Paquette Ronald L; Klisovic Rebecca B; Caligiuri Michael A; Cooper Michael R; Lecerf Jean-Michel; Karol Michael D; Sheng Shihong; Holford Nick; Curtin Peter T; Druker Brian J; Heinrich Michael C
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
Blood 2006;108(12):3674-81.
-
2006: Heinrich Michael C; Corless Christopher L
Does tumor mutational status correlate with clinical response to imatinib?
Nature clinical practice. Oncology 2006;3(11):600-1.
-
2006: Corless Christopher L; Harrell Patina; Lacouture Mario; Bainbridge Troy; Le Claudia; Gatter Ken; White Clifton; Granter Scott; Heinrich Michael C
Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia.
The Journal of molecular diagnostics : JMD 2006;8(5):604-12.
-
2006: Schittenhelm M M; Yee K W H; Tyner J W; McGreevey L; Haley A D; Town A; Griffith D J; Bainbridge T; Braziel R M; O'Farrell A-M; Cherrington J M; Heinrich M C
FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(11):2008-14.
-
2006: Demetri George D; van Oosterom Allan T; Garrett Christopher R; Blackstein Martin E; Shah Manisha H; Verweij Jaap; McArthur Grant; Judson Ian R; Heinrich Michael C; Morgan Jeffrey A; Desai Jayesh; Fletcher Christopher D; George Suzanne; Bello Carlo L; Huang Xin; Baum Charles M; Casali Paolo G
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
Lancet 2006;368(9544):1329-38.
-
2006: Heinrich Michael C; Corless Christopher L; Blanke Charles D; Demetri George D; Joensuu Heikki; Roberts Peter J; Eisenberg Burton L; von Mehren Margaret; Fletcher Christopher D M; Sandau Katrin; McDougall Karen; Ou Wen-bin; Chen Chang-Jie; Fletcher Jonathan A
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(29):4764-74.
-
2006: Walters Denise K; Goss Valerie L; Stoffregen Eric P; Gu Ting-Lei; Lee Kimberly; Nardone Julie; McGreevey Laura; Heinrich Michael C; Deininger Michael W; Polakiewicz Roberto; Druker Brian J
Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes.
Leukemia research 2006;30(9):1097-104.
-
2006: Walters Denise K; Mercher Thomas; Gu Ting-Lei; O'Hare Thomas; Tyner Jeffrey W; Loriaux Marc; Goss Valerie L; Lee Kimberly A; Eide Christopher A; Wong Matthew J; Stoffregen Eric P; McGreevey Laura; Nardone Julie; Moore Sandra A; Crispino John; Boggon Titus J; Heinrich Michael C; Deininger Michael W; Polakiewicz Roberto D; Gilliland D Gary; Druker Brian J
Activating alleles of JAK3 in acute megakaryoblastic leukemia.
Cancer cell 2006;10(1):65-75.
-
2006: Lam Maggie M; Corless Christopher L; Goldblum John R; Heinrich Michael C; Downs-Kelly Erinn; Rubin Brian P
Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfall.
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2006;25(3):288-92.
-
2006: Goldman Devorah C; Berg Linnea K; Heinrich Michael C; Christian Jan L
Ectodermally derived steel/stem cell factor functions non-cell autonomously during primitive erythropoiesis in Xenopus.
Blood 2006;107(8):3114-21.
-
2006: Mehrany Khosrow; Swanson Neil A; Heinrich Michael C; Weenig Roger H; Lee Ken K; White Clifton R; Devere Theresa S
Dermatofibrosarcoma protuberans: a partial response to imatinib therapy.
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2006;32(3):456-9.
-
2006: Heinrich Michael C; McArthur Grant A; Demetri George D; Joensuu Heikki; Bono Petri; Herrmann Richard; Hirte Hal; Cresta Sara; Koslin D Bradley; Corless Christopher L; Dirnhofer Stephan; van Oosterom Allan T; Nikolova Zariana; Dimitrijevic Sasa; Fletcher Jonathan A
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(7):1195-203.
-
2006: Einhorn Lawrence H; Brames Mary J; Heinrich Michael C; Corless Christopher L; Madani Ali
Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT.
American journal of clinical oncology 2006;29(1):12-3.
-
2006: Sengupta Shomik; Cheville John C; Corless Christopher L; Lohse Christine M; Heinrich Michael C; Kwon Eugene D; Zincke Horst; Blute Michael L; Leibovich Bradley C
Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinoma.
The Journal of urology 2006;175(1):53-6.
-
2006: Schittenhelm Marcus M; Shiraga Sharon; Schroeder Arin; Corbin Amie S; Griffith Diana; Lee Francis Y; Bokemeyer Carsten; Deininger Michael W N; Druker Brian J; Heinrich Michael C
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Cancer research 2006;66(1):473-81.
-
2005: O'Riain Ciarán; Corless Christopher L; Heinrich Michael C; Keegan Denise; Vioreanu Mihai; Maguire Donal; Sheahan Kieran
Gastrointestinal stromal tumors: insights from a new familial GIST kindred with unusual genetic and pathologic features.
The American journal of surgical pathology 2005;29(12):1680-3.
-
2005: Crossman L C; O'Hare T; Lange T; Willis S G; Stoffregen E P; Corbin A S; O'Brien S G; Heinrich M C; Druker B J; Middleton P G; Deininger M W N
A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(11):1859-62.
-
2005: Levine Ross L; Loriaux Marc; Huntly Brian J P; Loh Mignon L; Beran Miroslav; Stoffregen Eric; Berger Roland; Clark Jennifer J; Willis Stephanie G; Nguyen Kim T; Flores Nikki J; Estey Elihu; Gattermann Norbert; Armstrong Scott; Look A Thomas; Griffin James D; Bernard Olivier A; Heinrich Michael C; Gilliland D Gary; Druker Brian; Deininger Michael W N
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.
Blood 2005;106(10):3377-9.
-
2005: Goemans Bianca F; Zwaan Christian M; Harlow Amy; Loonen Anne H; Gibson Brenda E S; Hählen Karel; Reinhardt Dirk; Creutzig Ursula; Heinrich Michael C; Kaspers Gertjan J L
In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets.
Blood 2005;106(10):3532-7.
-
2005: O'Hare Thomas; Walters Denise K; Stoffregen Eric P; Sherbenou Daniel W; Heinrich Michael C; Deininger Michael W N; Druker Brian J
Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 1):6987-93.
-
2005: Blanke Charles; Eisenberg Burton L; Heinrich Michael
Epidemiology of GIST.
The American journal of gastroenterology 2005;100(10):2366.
-
2005: Gotlib Jason; Berubé Caroline; Growney Joseph D; Chen Ching-Cheng; George Tracy I; Williams Christopher; Kajiguchi Tomohiro; Ruan Jia; Lilleberg Stan L; Durocher Jeffrey A; Lichy Jack H; Wang Yanfeng; Cohen Pamela S; Arber Daniel A; Heinrich Michael C; Neckers Len; Galli Stephen J; Gilliland D Gary; Coutré Steven E
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.
Blood 2005;106(8):2865-70.
-
2005: Goemans B F; Zwaan C M; Martinelli S; Harrell P; de Lange D; Carta C; Reinhardt D; Hählen K; Creutzig U; Tartaglia M; Heinrich M C; Kaspers G J L
Differences in the prevalence of PTPN11 mutations in FAB M5 paediatric acute myeloid leukaemia.
British journal of haematology 2005;130(5):801-3.
-
2005: Goemans B F; Zwaan C M; Miller M; Zimmermann M; Harlow A; Meshinchi S; Loonen A H; Hählen K; Reinhardt D; Creutzig U; Kaspers G J L; Heinrich M C
Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(9):1536-42.
-
2005: Corless Christopher L; Schroeder Arin; Griffith Diana; Town Ajia; McGreevey Laura; Harrell Patina; Shiraga Sharon; Bainbridge Troy; Morich Jason; Heinrich Michael C
PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(23):5357-64.
-
2005: Subramanian Subbaya; West Robert B; Marinelli Robert J; Nielsen Torsten O; Rubin Brian P; Goldblum John R; Patel Rajiv M; Zhu Shirley; Montgomery Kelli; Ng Tony L; Corless Christopher L; Heinrich Michael C; van de Rijn Matt
The gene expression profile of extraskeletal myxoid chondrosarcoma.
The Journal of pathology 2005;206(4):433-44.
-
2005: Corbin Amie S; Demehri Shadmehr; Griswold Ian J; Wang Yihan; Metcalf Chester A; Sundaramoorthi Raji; Shakespeare William C; Snodgrass Joseph; Wardwell Scott; Dalgarno David; Iuliucci John; Sawyer Tomi K; Heinrich Michael C; Druker Brian J; Deininger Michael W N
In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit.
Blood 2005;106(1):227-34.
-
2005: O'Hare Thomas; Walters Denise K; Stoffregen Eric P; Jia Taiping; Manley Paul W; Mestan Jürgen; Cowan-Jacob Sandra W; Lee Francis Y; Heinrich Michael C; Deininger Michael W N; Druker Brian J
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
Cancer research 2005;65(11):4500-5.
-
2005: Heinrich Michael C; Corless Christopher L
Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy.
Journal of surgical oncology 2005;90(3):195-207; discussion 207.
-
2005: Li Frederick P; Fletcher Jonathan A; Heinrich Michael C; Garber Judy E; Sallan Stephen E; Curiel-Lewandrowski Clara; Duensing Anette; van de Rijn Matt; Schnipper Lowell E; Demetri George D
Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(12):2735-43.
-
2005: Walters Denise K; Stoffregen Eric P; Heinrich Michael C; Deininger Michael W; Druker Brian J
RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518.
Blood 2005;105(7):2952-4.
-
2005: McArthur Grant A; Demetri George D; van Oosterom Allan; Heinrich Michael C; Debiec-Rychter Maria; Corless Christopher L; Nikolova Zariana; Dimitrijevic Sasa; Fletcher Jonathan A
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(4):866-73.
-
2004: Corbin Amie S; Griswold Ian J; La Rosée Paul; Yee Kevin W H; Heinrich Michael C; Reimer Corinne L; Druker Brian J; Deininger Michael W N
Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.
Blood 2004;104(12):3754-7.
-
2004: Yee Kevin W H; Schittenhelm Marcus; O'Farrell Anne-Marie; Town Ajia R; McGreevey Laura; Bainbridge Troy; Cherrington Julie M; Heinrich Michael C
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.
Blood 2004;104(13):4202-9.
-
2004: Corless Christopher L; McGreevey Laura; Town Ajia; Schroeder Arin; Bainbridge Troy; Harrell Patina; Fletcher Jonathan A; Heinrich Michael C
KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors.
The Journal of molecular diagnostics : JMD 2004;6(4):366-70.
-
2004: Griswold Ian J; Shen Lei J; La Rosée Paul; Demehri Shadmehr; Heinrich Michael C; Braziel Rita M; McGreevey Laura; Haley Andrea D; Giese Neill; Druker Brian J; Deininger Michael W N
Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis.
Blood 2004;104(9):2912-8.
-
2004: Subramanian Subbaya; West Robert B; Corless Christopher L; Ou Wenbin; Rubin Brian P; Chu Kent-Man; Leung Suet Yi; Yuen Siu Tsan; Zhu Shirley; Hernandez-Boussard Tina; Montgomery Kelli; Nielsen Torsten O; Patel Rajiv M; Goldblum John R; Heinrich Michael C; Fletcher Jonathan A; van de Rijn Matt
Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles.
Oncogene 2004;23(47):7780-90.
-
2004: Corless Christopher L; Fletcher Jonathan A; Heinrich Michael C
Biology of gastrointestinal stromal tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(18):3813-25.
-
2004: Duensing Anette; Joseph Nora E; Medeiros Fabiola; Smith Felicity; Hornick Jason L; Heinrich Michael C; Corless Christopher L; Demetri George D; Fletcher Christopher D M; Fletcher Jonathan A
Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs).
Cancer research 2004;64(15):5127-31.
-
2004: Borg Christophe; Terme Magali; Taïeb Julien; Ménard Cédric; Flament Caroline; Robert Caroline; Maruyama Koji; Wakasugi Hiro; Angevin Eric; Thielemans Kris; Le Cesne Axel; Chung-Scott Véronique; Lazar Vladimir; Tchou Isabelle; Crépineau Florent; Lemoine François; Bernard Jacky; Fletcher Jonhantan A; Turhan Ali; Blay Jean-Yves; Spatz Alain; Emile Jean-François; Heinrich Michael C; Mécheri Salah; Tursz Thomas; Zitvogel Laurence
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.
The Journal of clinical investigation 2004;114(3):379-88.
-
2004: Medeiros Fabiola; Corless Christopher L; Duensing Anette; Hornick Jason L; Oliveira Andre M; Heinrich Michael C; Fletcher Jonathan A; Fletcher Christopher D M
KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications.
The American journal of surgical pathology 2004;28(7):889-94.
-
2004: West Robert B; Corless Christopher L; Chen Xin; Rubin Brian P; Subramanian Subbaya; Montgomery Kelli; Zhu Shirley; Ball Catherine A; Nielsen Torsten O; Patel Rajiv; Goldblum John R; Brown Patrick O; Heinrich Michael C; van de Rijn Matt
The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status.
The American journal of pathology 2004;165(1):107-13.
-
2004: Bono Petri; Krause Andreas; von Mehren Margaret; Heinrich Michael C; Blanke Charles D; Dimitrijevic Sasa; Demetri George D; Joensuu Heikki
Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib.
Blood 2004;103(8):2929-35.
-
2004: Deininger M W N; McGreevey L; Willis S; Bainbridge T M; Druker B J; Heinrich M C
Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(4):864-71.
-
2004: Heinrich Michael C
Targeting FLT3 kinase in acute myelogenous leukemia: progress, perils, and prospects.
Mini reviews in medicinal chemistry 2004;4(3):255-71.
-
2004: Hayes-Lattin Brandon; Seipel Timothy J; Gatter Ken; Heinrich Michael C; Maziarz Richard T
Pure red cell aplasia associated with parvovirus B19 infection occurring late after allogeneic bone marrow transplantation.
American journal of hematology 2004;75(3):142-5.
-
2004: Kemmer Kathleen; Corless Christopher L; Fletcher Jonathan A; McGreevey Laura; Haley Andrea; Griffith Diana; Cummings Oscar W; Wait Cecily; Town Ajia; Heinrich Michael C
KIT mutations are common in testicular seminomas.
The American journal of pathology 2004;164(1):305-13.
-
2004: Heinrich Michael C; Corless Christopher L
Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomas.
Cancer treatment and research 2004;120():129-50.
-
2004: Duensing Anette; Heinrich Michael C; Fletcher Christopher D; Fletcher Jonathan A
Biology of gastrointestinal stromal tumors: KIT mutations and beyond.
Cancer investigation 2004;22(1):106-16.
-
2004: Al-Ali Haifa-Kathrin; Heinrich Michael Charles; Lange Thoralf; Krahl Rainer; Mueller Matthias; Müller Christel; Niederwieser Dietger; Druker Brian James; Deininger Michael Werner Nikolaus
High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.
The hematology journal : the official journal of the European Haematology Association / EHA 2004;5(1):55-60.
-
2003: Heinrich Michael C
Is KIT an important therapeutic target in small cell lung cancer?
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(16 Pt 1):5825-8.
-
2003: Heinrich Michael C; Corless Christopher L; Demetri George D; Blanke Charles D; von Mehren Margaret; Joensuu Heikki; McGreevey Laura S; Chen Chang-Jie; Van den Abbeele Annick D; Druker Brian J; Kiese Beate; Eisenberg Burton; Roberts Peter J; Singer Samuel; Fletcher Christopher D M; Silberman Sandra; Dimitrijevic Sasa; Fletcher Jonathan A
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(23):4342-9.
-
2003: O'Farrell Anne-Marie; Foran James M; Fiedler Walter; Serve Hubert; Paquette Ron L; Cooper Maureen A; Yuen Helene A; Louie Sharianne G; Kim Heidi; Nicholas Susan; Heinrich Michael C; Berdel Wolfgang E; Bello Carlo; Jacobs Mark; Scigalla Paul; Manning William C; Kelsey Stephen; Cherrington Julie M
An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5465-76.
-
2003: Cruz Frank; Rubin Brian P; Wilson David; Town Ajia; Schroeder Arin; Haley Andrea; Bainbridge Troy; Heinrich Michael C; Corless Christopher L
Absence of BRAF and NRAS mutations in uveal melanoma.
Cancer research 2003;63(18):5761-6.
-
2003: Madani A; Kemmer K; Sweeney C; Corless C; Ulbright T; Heinrich M; Einhorn L
Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(6):873-80.
-
2003: Gazit Aviv; Yee Kevin; Uecker Andrea; Böhmer Frank-D; Sjöblom Tobias; Ostman Arne; Waltenberger Johannes; Golomb Gershon; Banai Shmuel; Heinrich Michael C; Levitzki Alexander
Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit.
Bioorganic & medicinal chemistry 2003;11(9):2007-18.
-
2003: O'Farrell Anne-Marie; Abrams Tinya J; Yuen Helene A; Ngai Theresa J; Louie Sharianne G; Yee Kevin W H; Wong Lily M; Hong Weiru; Lee Leslie B; Town Ajia; Smolich Beverly D; Manning William C; Murray Lesley J; Heinrich Michael C; Cherrington Julie M
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
Blood 2003;101(9):3597-605.
-
2003: Bauer Sebastian; Corless Christopher L; Heinrich Michael C; Dirsch Olaf; Antoch Gerald; Kanja Jörg; Seeber Siegfried; Schütte Jochen
Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.
Cancer chemotherapy and pharmacology 2003;51(3):261-5.
-
2003: Heinrich Michael C; Corless Christopher L; Duensing Anette; McGreevey Laura; Chen Chang-Jie; Joseph Nora; Singer Samuel; Griffith Diana J; Haley Andrea; Town Ajia; Demetri George D; Fletcher Christopher D M; Fletcher Jonathan A
PDGFRA activating mutations in gastrointestinal stromal tumors.
Science (New York, N.Y.) 2003;299(5607):708-10.
-
2002: Moses Ashlee V; Jarvis Michael A; Raggo Camilo; Bell Yolanda C; Ruhl Rebecca; Luukkonen B G Mattias; Griffith Diana J; Wait Cecily L; Druker Brian J; Heinrich Michael C; Nelson Jay A; Fruh Klaus
A functional genomics approach to Kaposi's sarcoma.
Annals of the New York Academy of Sciences 2002;975():180-91.
-
2002: Yee Kevin W H; O'Farrell Anne Marie; Smolich Beverly D; Cherrington Julie M; McMahon Gerald; Wait Cecily L; McGreevey Laura S; Griffith Diana J; Heinrich Michael C
SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.
Blood 2002;100(8):2941-9.
-
2002: Demetri George D; von Mehren Margaret; Blanke Charles D; Van den Abbeele Annick D; Eisenberg Burton; Roberts Peter J; Heinrich Michael C; Tuveson David A; Singer Samuel; Janicek Milos; Fletcher Jonathan A; Silverman Stuart G; Silberman Sandra L; Capdeville Renaud; Kiese Beate; Peng Bin; Dimitrijevic Sasa; Druker Brian J; Corless Christopher; Fletcher Christopher D M; Joensuu Heikki
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
The New England journal of medicine 2002;347(7):472-80.
-
2002: Fletcher Jonathan A; Fletcher Christopher D M; Rubin Brian P; Ashman Leonie K; Corless Christopher L; Heinrich Michael C
KIT gene mutations in gastrointestinal stromal tumors: more complex than previously recognized?
The American journal of pathology 2002;161(2):737-8; author reply 738-9.
-
2002: Moses Ashlee V; Jarvis Michael A; Raggo Camilo; Bell Yolanda C; Ruhl Rebecca; Luukkonen B G Mattias; Griffith Diana J; Wait Cecily L; Druker Brian J; Heinrich Michael C; Nelson Jay A; Früh Klaus
Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells.
Journal of virology 2002;76(16):8383-99.
-
2002: Dai Mu-Shui; Chevallier Nathalie; Stone Stacie; Heinrich Michael C; McConnell Melanie; Reuter Tanja; Broxmeyer Hal E; Licht Jonathan D; Lu Li; Hoatlin Maureen E
The effects of the Fanconi anemia zinc finger (FAZF) on cell cycle, apoptosis, and proliferation are differentiation stage-specific.
The Journal of biological chemistry 2002;277(29):26327-34.
-
2002: Heinrich Michael C; Rubin Brian P; Longley B Jack; Fletcher Jonathan A
Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations.
Human pathology 2002;33(5):484-95.
-
2002: Dematteo Ronald P; Heinrich Michael C; El-Rifai Wa'el M; Demetri George
Clinical management of gastrointestinal stromal tumors: before and after STI-571.
Human pathology 2002;33(5):466-77.
-
2002: Corless Christopher L; McGreevey Laura; Haley Andrea; Town Ajia; Heinrich Michael C
KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size.
The American journal of pathology 2002;160(5):1567-72.
-
2002: Heinrich Michael C; Blanke Charles D; Druker Brian J; Corless Christopher L
Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1692-703.
-
2002: Mauro Michael J; O'Dwyer Michael; Heinrich Michael C; Druker Brian J
STI571: a paradigm of new agents for cancer therapeutics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):325-34.
-
2001: Blanke C D; Eisenberg B L; Heinrich M C
Gastrointestinal stromal tumors.
Current treatment options in oncology 2001;2(6):485-91.
-
2001: Rader A E; Avery A; Wait C L; McGreevey L S; Faigel D; Heinrich M C
Fine-needle aspiration biopsy diagnosis of gastrointestinal stromal tumors using morphology, immunocytochemistry, and mutational analysis of c-kit.
Cancer 2001;93(4):269-75.
-
2001: Doolittle N D; Muldoon L L; Brummett R E; Tyson R M; Lacy C; Bubalo J S; Kraemer D F; Heinrich M C; Henry J A; Neuwelt E A
Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(3):493-500.
-
2000: Lu L; Dai M S; Ge Y; Wang L S; Braun S E; Wait C L; Griffith D J; Heinrich M C; Broxmeyer H E
Co-transduction of cDNAs for c-kit and steel factor into single CD34+ cord blood cells further enhances the growth of erythroid and multipotential progenitors.
Journal of hematotherapy & stem cell research 2000;9(6):813-25.
-
2000: Siess D C; Vedder C T; Merkens L S; Tanaka T; Freed A C; McCoy S L; Heinrich M C; Deffebach M E; Bennett R M; Hefeneider S H
A human gene coding for a membrane-associated nucleic acid-binding protein.
The Journal of biological chemistry 2000;275(43):33655-62.
-
2000: Heinrich M C; Griffith D J; Druker B J; Wait C L; Ott K A; Zigler A J
Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.
Blood 2000;96(3):925-32.
-
2000: Heinrich M C; Silvey K V; Stone S; Zigler A J; Griffith D J; Montalto M; Chai L; Zhi Y; Hoatlin M E
Posttranscriptional cell cycle-dependent regulation of human FANCC expression.
Blood 2000;95(12):3970-7.
-
2000: Dai M S; Heinrich M C; Broxmeyer H E; Lu L
Enhancing effects of co-transduction of both human erythropoietin receptor and c-kit cDNAs into hematopoietic stem/progenitor cells from cord blood on proliferation and differentiation of erythroid progenitors.
Cytokines, cellular & molecular therapy 2000;6(1):1-8.
-
1999: Lu L; Heinrich M C; Wang L S; Dai M S; Zigler A J; Chai L; Broxmeyer H E
Retroviral-mediated gene transduction of c-kit into single hematopoietic progenitor cells from cord blood enhances erythroid colony formation and decreases sensitivity to inhibition by tumor necrosis factor-alpha and transforming growth factor-beta1.
Blood 1999;94(7):2319-32.
-
1998: Hoatlin M E; Christianson T A; Keeble W W; Hammond A T; Zhi Y; Heinrich M C; Tower P A; Bagby G C
The Fanconi anemia group C gene product is located in both the nucleus and cytoplasm of human cells.
Blood 1998;91(4):1418-25.
-
1998: Tower P A; Christianson T A; Peters S T; Ostroski M L; Hoatlin M E; Zigler A J; Heinrich M C; Rathbun R K; Keeble W; Faulkner G R; Bagby G C
Expression of the Fanconi anemia group C gene in hematopoietic cells is not influenced by oxidative stress, cross-linking agents, radiation, heat, or mitotic inhibitory factors.
Experimental hematology 1998;26(1):19-26.
-
1998: Heinrich M C; Hoatlin M E; Zigler A J; Silvey K V; Bakke A C; Keeble W W; Zhi Y; Reifsteck C A; Grompe M; Brown M G; Magenis R E; Olson S B; Bagby G C
DNA cross-linker-induced G2/M arrest in group C Fanconi anemia lymphoblasts reflects normal checkpoint function.
Blood 1998;91(1):275-87.
-
1997: Rathbun R K; Faulkner G R; Ostroski M H; Christianson T A; Hughes G; Jones G; Cahn R; Maziarz R; Royle G; Keeble W; Heinrich M C; Grompe M; Tower P A; Bagby G C
Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells.
Blood 1997;90(3):974-85.
-
1996: Whitney M A; Royle G; Low M J; Kelly M A; Axthelm M K; Reifsteck C; Olson S; Braun R E; Heinrich M C; Rathbun R K; Bagby G C; Grompe M
Germ cell defects and hematopoietic hypersensitivity to gamma-interferon in mice with a targeted disruption of the Fanconi anemia C gene.
Blood 1996;88(1):49-58.
-
1995: Dooley D C; Oppenlander B K; Spurgin P; Mead J H; Novak F P; Plunkett M; Beckstead J; Heinrich M C
Basic fibroblast growth factor and epidermal growth factor downmodulate the growth of hematopoietic cells in long-term stromal cultures.
Journal of cellular physiology 1995;165(2):386-97.
-
1995: Heinrich M C; Dooley D C; Keeble W W
Transforming growth factor beta 1 inhibits expression of the gene products for steel factor and its receptor (c-kit).
Blood 1995;85(7):1769-80.
-
1994: Segal G M; Magenis R E; Brown M; Keeble W; Smith T D; Heinrich M C; Bagby G C
Repression of Fanconi anemia gene (FACC) expression inhibits growth of hematopoietic progenitor cells.
The Journal of clinical investigation 1994;94(2):846-52.
-
1993: Bagby G C; Segal G M; Auerbach A D; Onega T; Keeble W; Heinrich M C
Constitutive and induced expression of hematopoietic growth factor genes by fibroblasts from children with Fanconi anemia.
Experimental hematology 1993;21(11):1419-26.
-
1993: Heinrich M C; Dooley D C; Freed A C; Band L; Hoatlin M E; Keeble W W; Peters S T; Silvey K V; Ey F S; Kabat D
Constitutive expression of steel factor gene by human stromal cells.
Blood 1993;82(3):771-83.
-
1992: Bickler S W; Heinrich M C; Davey M; Harrison M W; Bagby G C
A method for rapid analysis of peripheral blood mononuclear leukocyte cytokine mRNA.
Experimental hematology 1992;20(8):980-5.
-
1992: Segal G M; Smith T D; Heinrich M C; Ey F S; Bagby G C
Specific repression of granulocyte-macrophage and granulocyte colony-stimulating factor gene expression in interleukin-1-stimulated endothelial cells with antisense oligodeoxynucleotides.
Blood 1992;80(3):609-16.
-
1992: Bickler S W; Heinrich M C; Bagby G C
Magnesium-dependent thermostability of DNase I.
BioTechniques 1992;13(1):64-6.
-
1991: Bagby G C; Heinrich M C
Vascular endothelial cells and hematopoiesis: regulation of gene expression in human vascular endothelial cells.
Hematologic pathology 1991;5(3):93-9.
-
1990: Hefeneider S H; Bennett R M; Pham T Q; Cornell K; McCoy S L; Heinrich M C
Identification of a cell-surface DNA receptor and its association with systemic lupus erythematosus.
The Journal of investigative dermatology 1990;94(6 Suppl):79S-84S.
-
1990: Bagby G C; Shaw G; Heinrich M C; Hefeneider S; Brown M A; DeLoughery T G; Segal G M; Band L
Interleukin-1 stimulation stabilizes GM-CSF mRNA in human vascular endothelial cells: preliminary studies on the role of the 3' AU rich motif.
Progress in clinical and biological research 1990;352():233-9.
-
1988: Bennet R M; Hefeneider S H; Bakke A; Merritt M; Smith C A; Mourich D; Heinrich M C
The production and characterization of murine monoclonal antibodies to a DNA receptor on human leukocytes.
Journal of immunology (Baltimore, Md. : 1950) 1988;140(9):2937-42.
-
1985: Carbone K M; Heinrich M C; Quinn T C
Thrombophlebitis and cellulitis due to Campylobacter fetus ssp. fetus. Report of four cases and a review of the literature.
Medicine 1985;64(4):244-50.
Sign-in to see more
